A new prostate cancer treatment has been rejected for use in Ireland, a move that is likely to reignite the debate about the state's refusal to pay for new medicines. Zytiga, which has been dubbed a 'wonder drug', can extend the lives of late-stage prostate cancer sufferers.
Earlier this month, the British National Health Service approved the drug for patients there. However, the National Centre for Pharmacoeconomics (NCPE), which carries out cost-effectiveness studies on new...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team